Skip to main content

Jeuveau FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 28, 2021.

FDA Approved: Yes (First approved February 1, 2019)
Brand name: Jeuveau
Generic name: prabotulinumtoxinA-xvfs
Dosage form: Injection
Company: Evolus, Inc.
Treatment for: Facial Wrinkles

Jeuveau (prabotulinumtoxinA) is a proprietary 900 kDa purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar (frown) lines.

Development timeline for Jeuveau

Feb  1, 2019Approval FDA Approves Jeuveau (prabotulinumtoxinA-xvfs) for Temporary Improvement in the Appearance of Frown Lines
Nov 19, 2018Evolus Receives Conditional FDA Acceptance of Jeuveau Brand Name
Aug 29, 2018Evolus Receives Acceptance of FDA BLA Resubmission for DWP-450

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.